RHBC
TTNP

R.H. Bluestein & Co’s Titan Pharmaceuticals TTNP Stock Holding History

R.H. Bluestein & Co’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6
Closed -$73K – 339
2017
Q1 		$73K Hold
6
– – ﹤0.01% 320
2016
Q4 		$80K Hold
6
– – 0.01% 301
2016
Q3 		$118K Hold
6
– – 0.01% 286
2016
Q2 		$109K Buy
+6
New +$128K 0.01% 283

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

R.H. Bluestein & Co's TTNP Position: Q2 2017 in Review

R.H. Bluestein & Co sold out of Titan Pharmaceuticals (TTNP) in Q2 2017, closing a stake of 6 shares — an estimated $73K sold.

R.H. Bluestein & Co first reported a position in TTNP in Q2 2016 and held it in 4 quarters. The position peaked at $118K in Q3 2016. 35 funds tracked by Wall St. Rank hold TTNP as of Q2 2017.

  • R.H. Bluestein & Co reported no remaining Titan Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • R.H. Bluestein & Co sold 6 Titan Pharmaceuticals shares in Q2 2017, an estimated $73K.
  • R.H. Bluestein & Co first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • R.H. Bluestein & Co's Titan Pharmaceuticals position peaked at $118K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2017.

Based on R.H. Bluestein & Co's 13F filing for Q2 2017, filed 11 Aug 2017.